Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 5,079 shares at $83.10 ($432K) on 2026-07-06, disclosed to the SEC on 2026-07-08.
Scheduled sale ($432k) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $83.10 | 313 | $26K | 6.0% |
| 2 | $83.10 | 387 | $32K | 7.4% |
| 3 | $84.41 | 1,036 | $87K | 20.2% |
| 4 | $84.41 | 833 | $70K | 16.3% |
| 5 | $85.84 | 645 | $55K | 12.8% |
| 6 | $85.84 | 519 |
| $45K |
| 10.3% |
| 7 | $86.38 | 745 | $64K | 14.9% |
| 8 | $86.38 | 601 | $52K | 12.0% |
| Total | $85.08 avg | 5,079 | $432K | 100% |
| Filing → |
| PTCT | SELL | 2026-08-19 | $204K | — | Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |